What the FDA labels say about taking them together
Temsirolimus and trandolapril
Trandolapril's FDA label of October 31, 2025 names temsirolimus in its drug interactions section; temsirolimus's label does not name trandolapril itself but warns about its class (ACE inhibitors). The trandolapril label: “Mammalian Target of Rapamycin (mTOR) Inhibitors Patients taking concomitant mTOR inhibitor therapy may be at increased risk for angioedema.”
Check it at the source: the temsirolimus FDA label on DailyMed (effective December 26, 2025, Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc.); the trandolapril FDA label on DailyMed (effective October 31, 2025, Lupin Pharmaceuticals, Inc.).
What does the temsirolimus label say about trandolapril?
Temsirolimus's label does not name trandolapril itself; it warns about its class (ACE inhibitors):
Temsirolimus label, drug interactionsIf alternative treatment cannot be administered, a dose adjustment should be considered [see Dosage and Administration (2.4) ]. Angioedema with ACE inhibitors and Calcium Channel Blockers Angioedema has been reported in patients taking mammalian target of rapamycin (mTOR) inhibitors in combination with ramipril and/or amlodipine.
Temsirolimus label, drug interactionsMonitor patients for signs and symptoms of angioedema when temsirolimus is given concomitantly with angiotensin converting enzyme (ACE) inhibitors (e.g., ramipril) or calcium channel blockers (CCB) (e.g., amlodipine).
Source: FDA drug label (Torisel), NDA022088 (Pf Prism Cv), as published by Wyeth Pharmaceuticals LLC, a subsidiary of Pfizer Inc., effective December 26, 2025 (SPL set 95b7dc92-2180-42f1-8699-3c28f609e674), via openFDA; the full label on DailyMed
What does the trandolapril label say about temsirolimus?
Trandolapril label, drug interactionsMammalian Target of Rapamycin (mTOR) Inhibitors Patients taking concomitant mTOR inhibitor (e.g., temsirolimus, sirolimus, everolimus) therapy may be at increased risk for angioedema ( see WARNINGS – Head and Neck Angioedema ).
Trandolapril label, warningsWhere there is involvement of the tongue, glottis, or larynx, likely to cause airway obstruction, emergency therapy, including but not limited to subcutaneous epinephrine solution 1:1,000 (0.3 to 0.5 mL) should be promptly administered. (See PRECAUTIONS - Information for Patients and ADVERSE REACTIONS .) Patients receiving coadministration of an ACE inhibitor with an mTOR (mammalian target of rapamycin) inhibitor (e.g., temsirolimus, sirolimus, everolimus) or a neprilysin inhibitor (e.g., sacubitril) may be at increased risk for angioedema.
Source: FDA drug label (Trandolapril), Lupin Pharmaceuticals, Inc., effective October 31, 2025 (SPL set 8143a6cf-dadc-4ef7-a8db-d16d7150ad34), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Temsirolimus | Trandolapril | |
|---|---|---|
| Labeled for | n/a | High blood pressure |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | n/a | $0.157 per tablet 1 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once